Investigators evaluated a 36-week community multicomponent exercise programme using the Vivifrail model in older adults and reported consistent functional improvement across two consecutive cycles. Ninety-two participants completed baseline and post-intervention assessments in the 2025–2026 cohort (mean age 75.9 years, 88.0% women); an independent 2024–2025 cohort of 86 participants was analysed jointly for replication, yielding a pooled sample of 178. The study team used a quasi-experimental, single-arm, repeated-measures service-evaluation design and explicitly noted that the design does not support causal inference.
The predefined primary outcome was the SPPB (Short Physical Performance Battery). Data indicated a mean increase in SPPB of 1.33 points in the pooled sample; the authors reported a large standardized effect (Cohen’s d = 0.96) and a p value < .001. The proportion of participants who reached the substantial minimal clinically important difference on SPPB was 72.8% as reported by the investigators. Secondary performance measures—Timed Up and Go (TUG), handgrip strength, and 6-metre walk time—also showed statistically significant improvement, and the authors reported that all four secondary outcomes met a false-discovery-rate corrected threshold (all q < .005). Cognitive screening with the MMSE was included as a secondary measure and likewise changed concordantly according to the source.
Reported effect sizes for SPPB and several secondary outcomes were similar across the two cohorts, which the authors present as replication of the programme’s association with functional gains. The paper provides numerical summaries and statistical tests for within-subject change but does not attribute the improvements to a single programme component; details of exercise content and session frequency were not specified in the summary available in the source.
The authors assessed probable sarcopenia by EWGSOP2 criteria and reported a reduction in prevalence from 17.4% at baseline to 5.4% at post-intervention in the pooled sample (p = .006). This reduction in probable sarcopenia accompanied a shift in SPPB-based frailty categories toward higher functional strata (reported p < .001). The investigators also computed an elevated fall-risk indicator identically in both cohorts; pooled results showed a decline in elevated fall risk from 19.7% to 11.2% (p = .002).
These categorical shifts were presented alongside continuous-score improvements, and the authors numbered the clinical relevance of both types of change. The source did not provide granular, component-level adherence data or individual exercise prescriptions in the public abstract, so readers cannot link specific programme features to the sarcopenia or frailty outcomes from the text provided.
Effect sizes for SPPB, handgrip strength and 6-metre walk were reported as consistent between the two cohorts, supporting reproducibility across consecutive service cycles. The investigators tested Time × Cohort interactions for each outcome and found a significant interaction only for TUG, indicating that change in TUG performance differed between the cycles. The source reports this interaction but does not include mechanistic explanation or subgroup analyses that would clarify why TUG diverged while other outcomes did not.
Readers should note that the study pooled cohorts for several analyses and reported both cohort-level and pooled outcomes. The authors reported standard inferential statistics and effect sizes; however, the summary in the source did not include detailed protocol-level differences between cycles that might explain the single-outcome interaction for TUG.
The authors declare no competing interests and state that the project was performed as a service evaluation under national regulations; formal Institutional Review Board approval was not required under Spanish Law 14/2007 for non-experimental healthcare service audits, because the work used anonymised routine data and did not assign interventions for research purposes. Investigators confirmed that participant consent procedures and data handling complied with relevant guidelines and that data are available from the authors upon reasonable request.
The single-arm, quasi-experimental design prevents attribution of observed improvements solely to the Vivifrail programme; the authors explicitly acknowledge this limitation. The source did not provide detailed adherence metrics, session-level content, or protocol deviations in the abstracted text, so questions remain about which programme elements drove change and whether results would be replicated under randomized or controlled conditions. Future steps documented by the authors were not specified in the source material; likewise, the source does not report on longer-term follow-up beyond the 36-week post-intervention assessment.